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Background. It is unknown whether the duration of systemic immunosuppressive treatment after allogeneic nonmy-
eloablative hematopoietic cell transplantation (HCT) might influence the incidence, severity, timing, and/or cortico-
steroid-responsiveness of graft-versus-host disease (GVHD).
Methods.We retrospectively analyzed outcomes among 185 patients with hematologic malignancies who were given
grafts from HLA-matched related donors following conditioning with 2 Gy total body irradiation alone or in combi-
nation with fludarabine between December 1998 and March 2003. Postgrafting immunosuppression consisted of
mycophenolate mofetil (days 0–27) in combination with 3 different cyclosporine (CSP) regimens: taper from (A) days
35 to 56 (n107), (B) days 56 to 77 (n35), and (C) days 56 to 180 (n43).
Results. The overall incidences of grades II–IV and III–IV acute GVHD, and extensive chronic GVHDwere 52%, 13%,
and 56%, respectively. The duration of CSP prophylaxis did not significantly influence the overall rate of acute GVHD
(grade II–IV), extensive chronic GVHD, or non-relapse mortality. However, prolonged administration of CSP (group
C) was associated with a significantly decreased hazard of grades III–IV acute GVHD (HR 0.2, 95% CI [0.04, 0.9]) and
with an increased likelihood of discontinuing all systemic immunosuppression (HR 2.4, 95% CI [1.1, 5.2]) when
compared to the shortest course of CSP (group A).
Conclusion. Longer CSP duration decreased the risk of severe GVHD and increased the likelihood of discontinuing all
systemic immunosuppression after nonmyeloablative HCT with HLA-matched related grafts.
Keywords: Graft-versus-host disease, Nonmyeloablative conditioning, Allogeneic hematopoietic cell transplantation,
Cyclosporine.
(Transplantation 2006;81: 818–825)
The development of minimally toxic nonmyeloablativepreparative regimens for allogeneic hematopoietic cell
transplantation (HCT) has expanded the available treatment
options for patients who, due to older age or comorbid con-
ditions, would otherwise not be candidates for conventional
HCT. Compared to conventional HCT, nonmyeloablative
regimens are mainly immunosuppressive and aimed at pre-
venting immunologic graft rejection, while tumor eradica-
tion is mediated by graft-versus-tumor (GVT) effects elicited
by minor histocompatibility antigen (mHA) disparities be-
tween donors and recipients.
Regimen-related toxicities and early mortality after
HCT are substantially lower following nonablative compared
with conventional conditioning (1, 2). In addition, previous
studies have shown that the cumulative incidence of grade
II–IV acute graft-versus-host disease (GVHD) after nonabla-
tive HCT was lower than after myeloablative HCT (3). Nev-
ertheless, GVHDhas remained a problem. Even though graft-
versus-host (GVH) reactions are important for eradication of
underlying malignancies, it is unclear what duration and se-
verity of clinical GVHDare required for nonablative transplants
to be successful. Different immunosuppressive drug combina-
tionshavebeenevaluated inefforts todecrease the incidenceand
severity of GVHD (4–17). However, the optimal duration of
immunosuppressive therapy and themost effectivedrug combi-
nation to protect against GVHD have not been defined.
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Based on results of preclinical studies in a canine trans-
plant model (18), we have developed a clinical nonmyeloab-
lative preparative regimen consisting of low-dose total body
irradiation (TBI; 2 Gy at 7 cGy/min on day 0) with or without
fludarabine, followed by G-CSF–mobilized peripheral blood
mononuclear cell (G-PBMC) infusions and postgrafting im-
munosuppression with mycophenolate mofetil (MMF) and
cyclosporine (CSP). This regimen has been proven to bemin-
imally toxic and well tolerated when used in patients with
malignant and non-malignant hematologic diseases who
were ineligible for conventional HCT (19–23).
Owing to the evolution of nonablative transplant pro-
tocols during the past 7 years, the duration of CSP adminis-
tration in recipients of HLA-matched related grafts has been
extended from 56 to 77 or 180 days, while the duration of
MMF (days 0 to 27) was kept constant. In the present study
we retrospectively analyzed whether the duration of post-
graftingCSP influenced the incidence, severity, timing and/or
corticosteroid-responsiveness of GVHD.
PATIENTS ANDMETHODS
One hundred eighty-five consecutive patients with
hematologic malignancies who had HCT after nonmyelo-
ablative conditioning from HLA-matched related donors
were included in this analysis. Sixteen additional patients
were excluded from the intention-to-treat analysis because
the duration of CSP prophylaxis was not specified at the time
of transplantation. Transplants were performed between De-
cember 1998 and March 2003 at the Fred Hutchison Cancer
Research Center (FHCRC, n129), City of Hope National
Medical Center (n28), VAPuget SoundHealthCare System
(n20), and University of Torino (n8). Results were ana-
lyzed with data available as of December 16, 2003. Patients
signed forms approved by the individual institutions’ Institu-
tional Review Boards documenting informed consent to par-
ticipate in the clinical trials. All transplants were from related
donors who were serologically matched for HLA-A, -B, and
-C, and allele level matched for HLA-DRB1 and -DQB1.
Thirty-seven (20%) of the 185 patients had failed autologous
transplantation amedian of 21 (range, 5–127)months before
allogeneic transplantation.
Preparative Regimens
Patients were enrolled on 9 protocols that used 2 differ-
ent conditioning regimens: 2 Gy TBI alone (7 cGy/min; day 0;
n67) or 2 Gy TBI plus fludarabine (30mg/m2/day; days4
to 2; n118). Fifty-six of the 185 patients (30%) received
planned cytoreductive autologous transplants before the
nonmyeloablative allografts.
Immunosuppression after Transplant
All patients received MMF 15 mg/kg orally every 12 hr
from days 0–27 and CSP 6.25 mg/kg orally or 2.5 mg/kg in-
travenously every 12 hr starting at day3 or1, respectively.
Owing to the evolution of nonablative transplant protocols,
the duration of CSP prophylaxis varied. In the initial proto-
cols, all patients received CSP through day 35 with taper to
day 56. In an attempt at decreasing the observed incidence of
GVHD, the duration of CSP was lengthened from 56 days to
either 77 or 180 days in subsequent protocols. Patients were
stratified to receive CSP through day 77 or 180 based on the
perceived risk of recurrent or progressive disease. Patients
with underlying malignancies deemed to be at high risk for
recurrence were, in order to maximize GVT effects, pre-
scribed faster CSP tapers (day 56 with taper until day 77)
compared to those deemed to be at low risk for recurrence
(day 56 with taper until day 180). We retrospectively com-
pared outcomes of consecutive patients assigned to the fol-
lowing three CSP schedules: CSP at full doses until A) day 35
with taper until day 56 (n107); B) day 56 with taper until
day 77 (n35); C) day 56 with taper until day 180 (n43). In
the remainder of this manuscript, they will be referred to as
groups A, B, and C, respectively. In addition to analyzing
outcomes based on intention-to-treat, information regarding
the actual administration of CSP, in particular, CSP taper
initiation, discontinuation, and reasons for deviating from
the prescribed CSP schedules were recorded.
Disease Risk of Relapse
Patients were retrospectively divided into three differ-
ent groups (standard risk, high risk, and very high risk of
relapse) based on their disease status at time of HCT.
Standard risk included patients with acute myeloid or lym-
phoblastic leukemia in first complete remission (CR),myelo-
dysplastic syndrome-refractory anemia, chronicmyeloid leu-
kemia (CML) in first chronic phase, chronic lymphocytic
leukemia, low-grade non-Hodgkin lymphoma, high or inter-
mediate grade non-Hodgkin lymphoma in CR, Hodgkin dis-
ease in CR,multiplemyeloma inCR orwithminimal residual
disease. High risk included patients with CML in second
chronic phase, myeloproliferative disorders, multiple my-
eloma,Hodgkin disease, and high or intermediate grade non-
Hodgkin lymphoma not in CR. Very high risk included pa-
tients with acute leukemia greater than second CR, CML in
accelerated phase or blast crisis, and myelodysplastic syn-
drome-refractory anemia with excess blasts or in transforma-
tion.
GVHD Grading and Treatment
Diagnosis and clinical grading of acute and chronic
GVHD were performed according to established criteria (24,
25). Treatment decisions were based on the attending physi-
cians’ assessment of the severity of GVHD. In most cases,
biopsies were done to confirm clinical findings. The typical
primary treatment of acute GVHD consisted of prednisone
(1–2 mg/kg per day; taper started after 14 days), and CSP,
MMF, or both were usually resumed at full doses at the time
prednisone treatment was indicated. Prednisone with or
without CSP was also used for the primary treatment of ex-
tensive chronic GVHD. Information regarding the initiation
and discontinuation of prednisone, and other systemic im-
munosuppressive agents was collected retrospectively. This
information allowed determination of time of onset of both
acute and chronic GVHD and served as amarker for therapy-
responsiveness of GVHD.
Modulation of Immunosuppression after
Recurrence or Progression of Malignancy
In patients with recurrent or progressive malignant
disease without active GVHD who were still on systemic
immunosuppressive therapy, immunosuppressive drugs
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were usually rapidly tapered to induce GVT effects. Patients’
follow-ups were therefore truncated at the time the CSP dose
was tapered early as a result of suspected disease relapse or
progression. Therefore, our analysis did not include GVHD
events that occurred following changes in the prescribed immu-
nosuppression schedule due to relapse or progressive disease.
Among 59 patients with disease relapse or progression, CSPwas
either tapered or discontinued earlier than prescribed in seven
patients. Of these seven patients, two developed GVHD.
Donor Lymphocyte Infusion (DLI)
Twenty-two patients (12%) were treated with DLI for
disease relapse/progression or decreasing chimerism. GVHD
and immunosuppressive therapy events occurring after DLI
were not included in this analysis.
Graft Rejection
Five patients (3%) rejected their grafts (5% donor
CD3 T-cell chimerism), and GVHD, immunosuppressive
therapy outcomes, and progression/relapse events were not
included in this analysis if they occurred after rejection.
Statistical Analysis
Demographic factors were summarized using percent-
ages, medians, and range values. Statistical comparisons be-
tween factors were made using a Kruskal Wallis test for con-
tinuous outcomes and chi-square or Fisher’s exact tests for
categorical factors. Overall survival and progression-free sur-
vival were estimated by the Kaplan and Meier method. Cu-
mulative incidence curves were used to estimate acute and
extensive chronic GVHD, initiation of prednisone, discon-
tinuation of all immunosuppressive therapy, and relapse and
non-relapsemortality. Death, rejection, DLI, and relapse/dis-
ease progression were treated as competing risk events in
these analyses, where appropriate for each endpoint. In addi-
tion, initiation of CSP taper or CSP discontinuation due to
disease relapse/progression was treated as a competing risk
event for GVHDand immunosuppressive therapy endpoints.
Cumulative incidence of both grades II–IV and III–IV acute
GVHD used time of first GVHD symptoms as the onset time.
Cox proportional hazards models were used to evaluate uni-
variate and multivariate effects of covariates on time to event
outcomes. Possible confounding factors considered for inclu-
sion in multivariate models were patient age at transplant,
preparative regimen, primary disease risk group (‘standard,’
‘high,’ and ‘very high’), and the number of prior chemother-
apy regimens. All factors were considered together in multi-
variable models, and those that did not markedly affect the
hazard ratio for other factors and were not statistically signif-
icant themselves were eliminated. All P values for Cox regres-
sion were derived from likelihood ratio statistics and were
two-sided.
RESULTS
One hundred eighty-five patients with hematologic
malignancies were included in this study. Themedian patient
age was 55 (range, 18–73) years. Details regarding patient
characteristics are provided in Table 1. In part owing to the
evolution of transplant protocols, imbalances of patient char-
acteristics between the three different CSP taper groups ex-
isted with regards to the disease, preparative regimen, and
disease risk.
GVHD
Among the 185 patients included in this analysis, the
overall incidences of grades II–IV, III–IV acute GHVD, and
extensive chronic GVHD were 52%, 13%, and 56%, respec-
tively. The cumulative incidences of grades II–IV and III–IV
acute GVHD in CSP taper groups A, B, and C were
57%(n61), 43% (n15), 49% (n21), and 15% (n16),
20% (n7), 5% (n2), respectively. While the overall inci-
dences of grades II–IV acute GVHD were similar among the
three CSP taper groups (P0.76; Figure 1A), there was a
strong suggestion (P0.06) of a decreased hazard of grades
III–IV acute GVHD detected among patients assigned to the
longest CSP prophylaxis compared to those assigned to the
shortest prophylaxis (group C vs. A; HR 0.3, 95% CI [0.1,
1.3]). There was a significantly decreased hazard of grades
III–IV acute GVHD detected among patients assigned to the
longest CSP prophylaxis compared to those assigned to the
intermediate duration (group C vs. B; HR 0.2, 95% CI [0.04,
0.9], P0.02; Figure 1B). After adjusting for patient age, pre-
parative regimen, and disease risk in multivariate analysis,
there was a significantly decreased hazard of grades III–IV
acuteGVHDamongpatients assigned to the longest CSPpro-
phylaxis compared to those assigned to the shortest CSP pro-
phylaxis regimen (group C vs. A; HR 0.2, 95% CI [0.04, 0.9],
P0.01; Table 2). Adjusting for the number of prior chemo-
therapy regimens did not change this result (data not shown).
Multivariate analysis also showed increased risks of grades
III-IV acute GVHD among patients given fludarabine and
TBI compared to those given TBI alone (HR 5.2, 95%CI [0.7,
40.9]; P0.05; Table 2). Although the day 28 donor T-cell
chimerism was significantly different between groups A, B,
andC, the degree of donorT-cell chimerismdid not influence
the risk of subsequent acute grades III-IV GVHD in univari-
ate or multivariate analysis that adjusted for CSP taper group
(data not shown). With a median follow-up of 29 (range,
6–55) months (38 (range 23–55), 13 (range, 7–30) and 13
(range, 6–30) respectively for groups A, B and C) and 106
patients (57%) alive, there was a significantly decreased inci-
dence of extensive chronic GVHD among patients assigned
to receive CSP until day 180 compared to the shortest CSP
duration (group C vs. A, HR 0.6, 95% CI [0.4, 1.0]; P0.05;
Figure 1 C). However, after adjusting for patient age, prepar-
ative regimen, and disease risk in multivariate analysis, this
difference was merely a trend (group C vs. A, HR 0.7, 95%CI
[0.4, 1.2]; P0.14).
Corticosteroids were the first-line therapy for patients
who developed GVHD. Thus, prednisone initiation served as
a marker for the onset of both acute and chronic GVHD that
required systemic immunosuppression. The cumulative inci-
dences for prednisone initiation were similar among patients
in the three different CSP groups (P0.38; Figure 2). There-
fore, the intended CSP duration did not influence the time of
onset of acute or chronic GHVD requiring therapy.
Discontinuation of Systemic
Immunosuppression
Discontinuation of all systemic immunosuppressive
agents served as a marker for successful GVHD prophylaxis
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and/or responsiveness of GVHD to therapy. The cumulative
incidences of discontinuation of all systemic immunosup-
pression by 24 months were 25%, 16%, and 50% for groups
A, B, and C, respectively. There was a strong suggestion that
time to discontinuation of all systemic immunosuppression
was shorter for patients assigned to receiving CSP until day
180 (group C) compared to those assigned to receiving the
shortest duration of CSP (group A, P0.06; Figure 3). Differ-
ences between groups B and C were not statistically signifi-
cant (P0.12). When included in a multivariable model that
adjusted for age at transplant, preparative regimen, and dis-
ease risk, the association between longer duration of CSP ex-
posure and the likelihood of earlier discontinuation of sys-
temic immunosuppression became significant (group C vs.
group A; HR2.4, 95% CI [1.1, 5.2], P0.03). There was no
significant difference in the time to discontinuation of all
systemic immunosuppression according to the prescribed
duration of CSP prophylaxis among patients who developed
extensive chronic GVHD (P0.35).
Nonrelapse Mortality
Twenty-two of the 44 deaths from non-relapse causes
were GVHD related. The cumulative incidences of non-re-
lapse mortality (NRM) according to the prescribed duration
of CSP prophylaxis were not significantly different (P0.32;
Figure 4). Adjusting for patient age, preparative regimen, and
disease risk in multivariate analysis did not change this find-
ing. However, there was an increased hazard of NRM among
those patients who received fludarabine and TBI compared
to TBI alone as part of their conditioning (HR 3.5; 95% CI
[1.1, 11.4]; P0.02).
Risk of Recurrent Malignancy
As would be expected, the hazards of progression or
relapsewere significantly higher for patients in the “high” and
“very high” disease risk categories relative to “standard” risk
patients (both P0.01). In univariate analysis, we found a
significantly decreased hazard of relapse among patients as-
signed to group C compared to those assigned to group B
(HR 0.4; 95% CI [0.2, 1.0]; P0.04). This could be explained
by the fact that some transplant protocols used the perceived
likelihood of recurrent or progressive malignancy to assign
patients to a relatively faster or slowerCSP taper. After adjust-
ing for disease risk in multivariate analysis, however, there
was no significant association between the assigned duration
of prophylactic CSP and the risk of recurrentmalignancy (HR
0.5; 95% CI [0.2, 1.3]; P0.12).
Reason for Deviation from Prescribed CSP Taper
Schedules
The results reported thus far were based on “intention-
to-treat.” We sought to determine whether this type of anal-
ysis was a reasonable representation of the CSP regimen ad-
ministered to patients. Possible reasons for deviating from
the prescribed CSP regimen included GVHD, disease relapse
or progression, CSP toxicity, and death prior to CSP taper
TABLE 1. Patient characteristics
CSP day 35,
taper to day 56
CSP day 56,
taper to day 77
CSP day 56,
taper to day 180 P valuea
n 107 35 43
Median age, years (range) 53 (18–73) 56 (26–73) 57 (36–71) 0.35
Sex %, female/male 32/68 37/63 42/58 0.49
Disease, n (%) 0.02
CML 7 (7) 0 (0) 0 (0)
CLL 9 (8) 1 (3) 8 (19)
ALL/AML 9 (8) 6 (17) 2 (5)
MDS 18 (17) 6 (17) 4 (9)
NHL/HD 27 (25) 17 (49) 13 (30)
MM 35 (33) 5 (14) 16 (37)
Wald 2 (2) 0 (0) 0 (0)
Donor, n (%) 1.00
HLA matched sibling 106 (99) 35 (100) 43 (100)
HLA matched related (non-sibling) 1 (1) 0 (0) 0 (0)
Preparative regimens, n (%) 0.001
TBI, 2 Gy 24 (22) 0 (0) 0 (0)
Flu TBI, 2 Gy 48 (45) 32 (91) 25 (58)
Auto Flu TBI, 2 Gy 1 (1) 3 (9) 9 (21)
Auto TBI, 2 Gy 34 (32) 0 (0) 9 (21)
Disease risk, n (%) 0.001
Standard risk 51 (48) 12 (34) 32 (74)
High risk 48 (45) 20 (57) 11 (26)
Very high risk 8 (7) 3 (9) 0 (0)
DLI, n (%) 16 (15) 2 (6) 4 (9) 0.33
Rejection, n (%) 4 (4) 0 (0) 1 (2) 0.83
a Two-sided P values from Kruskal-Wallis test for age, chi-square or Fisher’s exact test for all other factors.
ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; Auto, autologous; CLL, chronic lymphocytic leukemia; CML, chronic myeloid
leukemia; DLI, donor lymphocyte infusion; FLU, fludarabine; HD, Hodgkin disease; MDS, myelodysplastic syndrome; MM, multiple myeloma; NHL, non-
Hodgkin lymphoma; TBI, total body irradiation; y, year; Wald, Waldenstro¨m’s disease.
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initiation. Among the 185 patients in this study, CSP was
tapered as originally prescribed per protocol in 103 patients
(56%). In 6 patients (4%), the CSP taper was initiated early
due to either recurrent or progressive malignancy (n3; 2%)
or CSP toxicity (n3; 2%). Nine patients (5%) died before
the prescribed initiation of the CSP taper, and in 52 patients
(28%) the initiation of the CSP taper was delayed because of
the development ofGVHD. For 15 patients (8%), the times of
initiating or the reasons for delaying the CSP taper could not
be determined. The proportions of patients who initiated the
CSP taper according to respective transplant protocols were
64%, 46%, and 44% for groups A, B, and C, respectively
(P0.04). However, in all three patient groups, the primary
reason for not initiating the CSP taper according to protocol
was the development of GVHD (21%, 34%, and 42% for
groups A, B, and C, respectively).
Tempo of CSP Withdrawal and Risk of Severe
GVHD
To determine whether there was a possible association
between the tempo of CSPwithdrawal and the risk of GVHD,
data from patients in groups A, B and C who were alive with-
out GVHD at day 56, were analyzed for the subsequent oc-
currence of GVHD. After adjusting for preparative regimen,
age at transplant, and disease risk in multivariate Cox regres-
sion analysis, the tempo of CSP withdrawal in group A com-
pared toCwas a significant risk factor for grades II–IVGVHD
(P0.01), however, was not a significant risk factor for grades
II-IV acute GVHD in group B compared to C (P0.36). Due
to the small number of events of grades III–IV acute GVHD
after day 56 (13, 3 and 0 for groups A, B and C, respectively),
a similar Cox regression analysis could not be performed.
Instead, a univariate log rank test found a decreased risk of
grade III–IV acute GVHD after day 56 among patients in
groupC compared to those in groupA (P0.03) and group B
(P0.04).
DISCUSSION
The analysis showed that recipients of nonmyelo-
ablative transplants from HLA-matched related donors who
were assigned to a prolonged course of postgrafting CSP (180
days vs. 56 or 77 days), had a statistically significant decreased
risk of severe (grades III–IV) acute GVHD and an increased
likelihood of discontinuing systemic immunosuppressive
therapy. The risk of developing extensive chronic GVHDwas
not affected by the prescribed duration of the CSP prophy-
laxis.
Even though GVH-reactions ensuing after nonmyelo-
ablative HCT are, in theory, needed for achieving stable en-
graftment and for eradication of the underlying malignant
diseases, the prevention of severe acute GVHD and its docu-
mented associated morbidity and mortality have remained
important objectives (26–29). A recent study among recipi-
ents of HLA-matched related and unrelated nonmyeloabla-
tive transplants conducted at our institution demonstrated
that grades III–IV acute GVHD resulted in significantly in-
creased non-relapse mortality without measurable protective
effects against recurrent malignancies. The protective effects
against disease recurrence and the consequent superior pro-
gression-free survival were exclusively associated with exten-
sive chronic GVHD (30). In light of these results, the preven-
tion of (severe) acute GVHD appeared to be more desirable
than the prevention of chronic GVHD. The current analysis
suggested that the risk of severe acute GVHD could be mini-
mized without affecting the risk of chronic GVHD by pre-
scribing at least 2months of CSP, followed by a taper over the
subsequent 4 months.
FIGURE 1. Intention-to-treat analysis. (A) Probability of
acuteGVHD (grades 2–4) according to duration ofCSPpro-
phylaxis. (B) Probability of severe acute GVHD (grades
3–4) according to duration of CSP prophylaxis. (C) Proba-
bility of extensive chronic GVHD according to duration of
CSP prophylaxis. (Extextensive). *P denotes value for
overall comparison among the three groups.
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The initiation of prednisone therapy served as amarker
for the onset of both acute and chronic GVHD. We did not
find significant differences in either the times to onset of
prednisone therapy nor in the cumulative incidences of pred-
nisone initiation among patients assigned to the three differ-
ent CSP groups. This suggested that maintenance of thera-
peutic CSP levels (150–400 ng/ml) until at least 2 months
after transplant, followed by a “slow” CSP taper (6% per
week) did not affect the time of onset or overall incidence of
grades II–IV acute GVHD but rather prevented progression
of this complication to grades III–IV acute GVHD.
A systematic analysis of the effects of the duration of
immunosuppressive prophylaxes on outcomes after nonmy-
eloablative HCT has not, to our knowledge, been performed.
Two randomized studies compared 2 vs. 6 months (31), and
6 vs. 24 months (32) of CSP given after myeloablative HCT
from HLA-identical siblings or HLA-matched unrelated do-
nors. Both studies failed to find significant differences in the
incidences of chronic GVHDandNRMamong patients given
the shorter compared to the longer CSP regimens. In con-
trast, two non-randomized studies among recipients of my-
eloablative transplants fromHLA-identical siblings suggested
that prolonged CSP prophylaxis (5months vs.5months;
and 12 vs. 6 months) was associated with protection against
chronic GVHD (33, 34). The impact of the duration of CSP
prophylaxis on the incidence or severity of acute GVHD
could not be addressed in previous studies because patients
were on CSP prophylaxis at the time acute GVHDdeveloped.
An important marker not only for the successful pre-
vention of GVHD but also for its therapy responsiveness has
been the discontinuation of all systemic immunosuppres-
sion. Multivariate analysis demonstrated a significantly in-
creased likelihood of discontinuing all systemic immunosup-
pression among patients assigned to receiving a prolonged
course of CSP (group C; intent to complete taper by day 180)
as compared to those assigned to receive the shortest course
of CSP (group A; intent to complete taper by day 56). Hence,
the relatively slow withdrawal of CSP not only decreased the
risk of severe acute GVHD but also appeared to facilitate the
eventual development of donor/recipient tolerance as evi-
denced by the ability to discontinue all systemic immunosup-
pressive therapy.
A potential limitation of this study was the fact that
TABLE 2. Multivariate analysis of severe acute GVHD grades 3–4
Variable
Adjusted
hazard ratio P value
95%
confidence
interval
CSP duration Day 35, taper to day 56 1.0 ––– –––
Day 56, taper to day 77 1.0 0.99 0.4, 2.7
Day 56, taper to day 180 0.2 0.01 0.04, 0.9
Conditioning regimen TBI 1.0 ––– –––
Flu TBI 5.2 0.05 0.7, 40.9
Auto Flu TBI 8.8 0.09 0.7, 114.2
Auto TBI 2.9 0.29 0.3, 24.6
Age (years) 55 1.0 ––– –––
55 1.1 0.76 0.5, 2.5
Disease risk Standard 1.0 ––– –––
High 1.1 0.77 0.5, 2.6
Very High 0.4 0.40 0.1, 3.6
Auto, autologous; FLU, fludarabine; TBI, total body irradiation.
FIGURE 2. Probability of prednisone initiation accord-
ing to duration of CSP prophylaxis. Intention-to-treat anal-
ysis. *P denotes value for overall comparison among the
three groups.
FIGURE 3. Probability of discontinuing all systemic im-
munosuppression according to duration of CSP prophy-
laxis. Intention-to-treat analysis. IS, immunosuppression.
*P denotes value for overall comparison among the three
groups.
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patients were evaluated based on “intention-to-treat.” How-
ever, an evaluation of incidence and severity of GVHD based
on actual durations of CSP exposure would have led to biased
results. For example, the primary reason patients remained
on CSP longer than specified by respective protocols was the
occurrence of GVHD. Therefore, an evaluation of the impact
of actual CSP exposure on the risk of GVHD would have led
to the circular conclusion that extending the CSP prophylaxis
increased the risk of GVHD.
Since these were not concurrent protocols, it is possible
that the differences in GVHD rates seen between protocol
groups could be explained by treatment changes over time.
Although we have attempted to adjust for specific factors
known to have changed over time, such as the addition of 3
doses of fludarabine to the 2 Gy TBI in the conditioning reg-
imen, it is possible that other factors changed that we did not
consider.
To address the potential limitation of an analysis by
intention-to-treat, we determined the incidence of GVHD
occurring after day 56 in a landmark analysis including all
patients in groups A, B and C who were alive without GVHD
at day 56. In spite of the relatively low number of events of
grades III–IV GVHD occurring after day 56 among the pa-
tients in the 3 groups (13, 3 and 0 for groups A, B and C,
respectively), the analysis suggested that a slower CSP taper
was associated with a protection against grades III-IV acute
GVHD, although this result should be confirmed due to the
small number of subjects available for analysis.
Finally, multivariate analysis adjusted for CSP expo-
sure, patient age, and disease risk showed that patients con-
ditioned with fludarabine and TBI compared to TBI alone
experienced both higher incidences of grade III–IV acute
GVHDandNRM. Fludarabine had been added to 2GyTBI in
a successful attempt to overcome the 20% incidence of non-
fatal graft rejections observed among the first 44 recipients of
nonmyeloablative transplants from HLA-matched related
donors after 2 Gy TBI alone (21). Subsequent analyses dem-
onstrated a significantly decreased incidence of graft rejection
in patients given fludarabine and TBI (3%) compared to
those given TBI alone (P0.001). While the risks of relapse
were similar between the two groups, patients conditioned
with fludarabine/TBI had a significantly increasedNRMfrom
infections compared to those given TBI only (P0.02) (22).
Given that these findings were based on retrospective anal-
yses of data from patients who were not transplanted concur-
rently, we are presently conducting a prospective, random-
ized, phase III study comparing conditioning with TBI versus
fludarabine/TBI.
In summary, we showed that after nonablative HCT
from HLA-matched related donors, a prescribed 2-month
course of CSP followed by a 4-month taper decreased the risk
of grades III–IV acute GVHD and increased the likelihood of
discontinuing all systemic immunosuppression when com-
pared to two shorter CSP regimens. Protection against severe
acute GVHD did not affect the risks of chronic GVHD or
relapse. Future prospective studies are needed to determine
whether substituting alternative calcineurin inhibitors, such
as tacrolimus, for CSP, or extending the use of antimetabo-
lites, such asMMF, beyond onemonth after transplantmight
be more effective in preventing severe or therapy-refractory
GVHD without compromising engraftment and control of
the underlying malignancies.
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